



CS/NSE/BSE/AFR/2017-18
May 19, 2017

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: 530239

Dear Sir/Madam,

Sub: Resubmission of audited standalone & consolidated Financial Results for the quarter & financial year ended 31st March 2017

Ref: Your email dt: 17-05-2017
.....

With reference to above and further to our letter dated 13th May, 2017 regarding outcome board meeting held on 13th May, 2017. We are resubmitting the Audited standalone & consolidated Financial Results of the Company for the quarter and financial year ended 31st March, 2017 as per schedule III of the Companies, Act, 2013.

We request you to take these documents on your records.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

A handwritten signature in black ink, appearing to read 'K Hanumantha Rao', is written over a horizontal line.

K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I Road No.5
Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LIMITED

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvlen.com website: www.suvlen.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2017

All amounts in Indian Rupees lakhs

Sl. No.	Particulars	For the Quarter Ended			For the Year Ended	
		31-Mar-2017	31-Dec-2016	31-Mar-2016	31-Mar-2017	31-Mar-2016
		Audited	Un-audited	Audited	Audited	Audited
1	Revenue from operations					
	(a) Net sales/income from operations (inclusive of excise duty)	17,499.64	11,539.43	16,937.20	53,916.74	50,028.18
	(b) Other operating income	515.15	15.89	-	531.04	-
	Total Revenue from operations	18,014.79	11,555.32	16,937.20	54,447.78	50,028.18
2	Other Income	493.85	490.15	423.18	2,109.25	1,929.36
	Total Income (1+2)	18,508.64	12,045.47	17,360.38	56,557.03	51,957.54
3	Expenses					
	(a) Cost of materials consumed	4,235.36	3,852.71	4,664.35	15,480.66	17,845.37
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,234.61	(1,607.90)	1,925.07	(295.94)	(1,205.21)
	(d) Employee benefits expense	1,453.53	1,262.91	926.49	5,064.46	4,094.43
	(e) Finance costs	156.82	126.47	167.52	566.58	587.21
	(f) Depreciation and amortisation expenses	718.31	487.20	557.49	2,141.31	1,749.71
	(g) Manufacturing expenses	2,531.43	1,975.74	2,172.23	8,157.37	7,522.01
	(h) Research & Development expenses	1,923.75	1,635.97	1,600.56	6,494.09	6,217.41
	(i) Other expenses	819.49	749.64	752.01	3,012.81	2,565.07
	Total expenses	14,073.30	8,482.74	12,765.72	40,621.34	39,376.00
4	Profit before exceptional items and tax (1+2-3)	4,435.34	3,562.73	4,594.66	15,935.69	12,581.54
5	Exceptional Items	-	-	-	-	-
6	Profit before tax (4 - 5)	4,435.34	3,562.73	4,594.66	15,935.69	12,581.54
7	Tax Expenses					
	(a) Current tax	143.47	949.47	891.84	3,275.07	2,580.06
	(b) Deferred tax	284.90	186.19	(14.98)	313.25	(6.51)
8	Net Profit for the period / year (6-7)	4,006.97	2,427.07	3,717.80	12,347.37	10,007.99
9	Other Comprehensive Income					
9.A	(i) Items that will not be reclassified to profit or loss	36.96	(17.29)	(17.28)	(14.90)	(69.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(12.79)	5.98	5.98	5.15	23.93
9.B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income	24.17	(11.31)	(11.30)	(9.75)	(45.23)
	Total Comprehensive Income (8+9)	4,031.14	2,415.76	3,706.50	12,337.62	9,962.76
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
11	Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each):					
	a) Basic	3.17	1.90	2.91	9.69	7.83
	b) Diluted	3.17	1.90	2.91	9.69	7.83

See accompanying notes to the financial statements

SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES

PARTICULARS	For the Quarter Ended			For the Year Ended	
	31-Mar-2017	31-Dec-2016	31-Mar-2016	31-Mar-2017	31-Mar-2016
	Audited	Un-audited	Audited	Audited	Audited
1 SEGMENT REVENUE					
a) Manufacturing (CRAMS)	17,500.16	10,682.46	16,344.52	51,670.07	46,710.87
b) Services (DDDSS)	514.63	856.99	516.64	2,777.71	3,241.37
c) Research & Development	-	-	-	-	-
Total	18,014.79	11,539.45	16,861.16	54,447.78	49,952.24
Less: Inter Segment Revenue	-	-	-	-	-
Net Sales/Income from Operations	18,014.79	11,539.45	16,861.16	54,447.78	49,952.24
2 SEGMENT RESULTS (Profit/(Loss) before tax and interest)					
a) Manufacturing (CRAMS)	6,342.38	4,999.12	6,213.67	21,634.85	17,391.75
b) Services (DDDSS)	275.68	439.15	307.44	1,476.81	1,982.52
c) Research & Development	(1,923.75)	(1,635.97)	(1,678.23)	(6,494.09)	(6,295.08)
TOTAL	4,694.31	3,802.30	4,842.88	16,617.57	13,079.19
Less: i) Finance Cost	75.01	93.12	109.93	376.38	406.52
ii) Other Un-allocable expenditure /(income), net	183.96	146.45	138.28	305.50	91.13
Total Profit Before Tax	4,435.34	3,562.73	4,594.67	15,935.69	12,581.54
3 SEGMENT ASSETS :					
a) Manufacturing (CRAMS)	43,886.93	51,397.78	43,091.01	43,886.93	43,091.01
b) Services (DDDSS)	2,828.60	2,693.72	3,631.42	2,828.60	3,631.42
c) Research & Development	2,609.60	2,489.66	2,880.34	2,609.60	2,880.34
d) Un allocated	38,291.82	29,713.48	27,774.68	38,291.82	27,774.68
TOTAL	87,616.95	86,294.64	77,377.45	87,616.95	77,377.45
4 SEGMENT LIABILITIES :					
a) Manufacturing (CRAMS)	8,547.86	8,727.74	7,820.34	8,547.86	7,820.34
b) Services (DDDSS)	370.23	491.00	338.72	370.23	338.72
c) Research & Development	1,848.18	2,113.04	1,690.88	1,848.18	1,690.88
d) Un allocated	687.23	803.03	628.73	687.23	628.73
TOTAL	11,453.50	12,134.81	10,478.67	11,453.50	10,478.67

Notes:

- 1) The above results were reviewed by Audit Committee and approved by the Board of Directors' Meeting held on 13th May 2017 and the same has been Reviewed by the Statutory Auditors.
- 2) Corresponding Previous period figures have been regrouped / reclassified where ever necessary.
- 3) The Board has declared and paid an Interim Dividend of Rs.1.00 per equity share (100% of face value of Rs.1.00 each) for the financial year 2016-17. The Board has recommended that the interim dividend paid will be treated as final dividend for the year 2016-17.
- 4) Reconciliation between financial results previously reported (referred to as "Previous GAAP") and Ind AS for the quarter and year ended 31 March 2016

	For the Quarter Ended 31/03/2016	For the Year Ended 31/03/2016
Net profit under previous GAAP (After Tax)	3,229.22	9,496.98
QIP issue expenses considered for grossing up to share premium account	484.68	484.68
Transitional effect on account of fair valuation of govt loans and reclassification of actuarial loss on employee ben	(14.48)	26.32
Deferred tax asset due to fair valuation of Mutual funds & actuarial loss on employee benefits	(5.55)	(23.93)
Net Profit under Ind AS (After Tax)	3,693.87	9,984.05
Other Comprehensive Income	12.63	(21.29)
Total Comprehensive Income Under Ind AS	3,706.50	9,962.76

For SUVEN LIFE SCIENCES LTD



Place: Hyderabad
Date: 13th May, 2017

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver

5) Statement of Asset and Liabilities

Particulars		As at 31-03-2017	As at 31-03-2016
		Audited Standalone	Audited Standalone
ASSETS			
1	Non-current assets		
	Property, plant and equipment	30,447.56	30,505.64
	Capital work-in-progress	971.64	719.73
	Other intangible assets	124.83	29.70
	Financial assets		
	Investments	6,507.72	2,305.15
	Loans	3.35	1.92
	Other financial assets	583.93	501.06
	Deferred tax assets (net)	189.55	497.63
	Other non-current assets	69.62	113.45
	Total non-current assets	38,898.20	34,674.28
2	Current assets		
	Inventories	9,251.14	8,346.44
	Financial assets		
	Investments	30,088.91	5.31
	Trade receivables	4,583.32	5,356.49
	Cash and cash equivalents	414.16	23,984.93
	Bank balance other than cash and cash equivalents	48.21	85.02
	Loans	7.57	11.52
	Other financial assets	0.71	2.55
	Current tax assets (net)	642.41	446.03
	Other current assets	3,682.32	4,464.88
	Total current assets	48,718.75	42,703.17
	TOTAL ASSETS	87,616.95	77,377.45
EQUITY AND LIABILITIES			
1	Equity		
	Equity share capital	1,272.82	1,272.82
	Other equity	71,880.10	61,074.42
	Total equity	73,152.92	62,347.24
2	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Borrowings	2,593.21	4,163.83
	Provisions	283.50	239.50
	Other non-current liabilities	133.82	148.21
	Total non-current liabilities	3,010.53	4,551.54
	Current liabilities		
	Financial liabilities		
	Borrowings	3,048.52	2,416.36
	Trade payables	6,078.14	5,405.45
	Other financial liabilities	1,737.66	2,227.31
	Other current liabilities	156.27	125.98
	Provisions (employee benefit obligations)	403.85	274.51
	Deferred government grants	29.06	29.06
	Total current liabilities	11,453.50	10,478.67
	Total liabilities	14,464.03	15,030.21
	TOTAL EQUITY AND LIABILITIES	87,616.95	77,377.45



SUVEN LIFE SCIENCES LIMITED

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvan.com website: www.suvan.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH 2017

All amounts in Indian Rupees lakhs

Sl. No.	Particulars	For the Year Ended	
		31-Mar-2017	31-Mar-2016
		Audited	Audited
1	Revenue from operations		
	(a) Net sales/income from operations (inclusive of excise duty)	53,916.74	50,028.18
	(b) Other operating income	531.04	-
	Total Revenue from operations	54,447.78	50,028.18
2	Other Income	2,109.25	1,929.36
	Total Income (1+2)	56,557.03	51,957.54
3	Expenses		
	(a) Cost of materials consumed	15,480.66	17,845.37
	(b) Purchases of stock-in-trade	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(295.94)	(1,205.21)
	(d) Employee benefits expense	5,216.57	4,094.43
	(e) Finance costs	568.34	587.63
	(f) Depreciation and amortisation expenses	2,141.31	1,749.71
	(g) Manufacturing expenses	8,157.37	7,522.01
	(h) Research & Development expenses	9,914.54	9,035.16
	(i) Other expenses	3,067.13	2,570.03
	Total expenses	44,249.98	42,199.13
4	Profit before exceptional items and tax (1+2-3)	12,307.05	9,758.41
5	Exceptional Items	-	-
6	Profit before tax (4 - 5)	12,307.05	9,758.41
7	Tax Expenses		
	(a) Current tax	3,275.07	2,580.06
	(b) Deferred tax	313.25	(6.51)
8	Net Profit for the period / year (6-7)	8,718.73	7,184.86
9	Other Comprehensive Income		
9.A	(i) Items that will not be reclassified to profit or loss	(14.90)	(69.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	5.16	23.94
9.B	(i) Items that will be reclassified to profit or loss	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-
	Total Other Comprehensive Income	(9.74)	(45.22)
	Total Comprehensive Income (8+9)	8,708.99	7,139.64
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82
11	Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each):		
	a) Basic	6.84	5.61
	b) Diluted	6.84	5.61

See accompanying notes to the financial statements

SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES

	PARTICULARS	For the Year Ended	
		31-Mar-2017	31-Mar-2016
		Audited	Audited
1	SEGMENT REVENUE		
	a) Manufacturing (CRAMS)	51,670.07	46,786.81
	b) Services (DDDSS)	2,777.71	3,241.37
	c) Research & Development	-	-
	Total	54,447.78	50,028.18
	Less: Inter Segment Revenue	-	-
	Net Sales/Income from Operations	54,447.78	50,028.18
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)		
	a) Manufacturing (CRAMS)	21,634.85	17,391.75
	b) Services (DDDSS)	1,474.14	1,945.31
	c) Research & Development	(10,066.65)	(9,035.16)
	TOTAL	13,042.34	10,301.90
	Less: i) Finance Cost	376.38	406.52
	ii) Other Un-allocable expenditure /(income), net	358.91	136.97
	Total Profit Before Tax	12,307.05	9,758.41
3	SEGMENT ASSETS :		
	a) Manufacturing (CRAMS)	43,659.63	42,899.22
	b) Services (DDDSS)	2,818.98	3,883.41
	c) Research & Development	2,860.30	2,867.29
	d) Un allocated	32,232.01	25,499.37
	TOTAL	81,570.92	75,149.29
4	SEGMENT LIABILITIES :		
	a) Manufacturing (CRAMS)	8,119.53	7,785.63
	b) Services (DDDSS)	352.40	343.28
	c) Research & Development	2,721.35	2,393.07
	d) Un allocated	667.23	547.29
	TOTAL	11,860.51	11,069.27

Notes:

- 1) The above results were reviewed by Audit Committee and approved by the Board of Directors' Meeting held on 13th May 2017 and the same has been Reviewed by the Statutory Auditors.
- 2) Corresponding Previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD



Place: Hyderabad
Date: 13th May, 2017

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver

3) Statement of Asset and Liabilities

Particulars		As at 31-03-2017	As at 31-03-2016
		Audited	Audited
		Consolidated	Consolidated
ASSETS			
1	Non-current assets		
	Property, plant and equipment	30,447.56	30,505.64
	Capital work-in-progress	971.64	719.73
	Other intangible assets	124.83	29.70
	Financial assets		
	Investments	7.05	7.05
	Loans	3.35	1.92
	Other financial assets	583.93	501.06
	Deferred tax assets (net)	189.55	497.63
	Other non-current assets	69.62	113.45
	Total non-current assets	32,397.53	32,376.18
2	Current assets		
	Inventories	9,251.14	8,346.44
	Financial assets		
	Investments	30,088.91	5.31
	Trade receivables	4,583.32	5,356.49
	Cash and cash equivalents	868.80	24,054.87
	Bank balance other than cash and cash equivalents	48.21	85.02
	Loans	7.57	11.52
	Other financial assets	0.71	2.55
	Current tax assets (net)	642.41	446.03
	Other current assets	3,682.32	4,464.88
	Total current assets	49,173.39	42,773.11
	TOTAL ASSETS	81,570.92	75,149.29
EQUITY AND LIABILITIES			
1	Equity		
	Equity share capital	1,272.82	1,272.82
	Other equity	65,427.06	58,255.66
	Total equity	66,699.88	59,528.48
2	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Borrowings	2,593.21	4,163.83
	Provisions	283.50	239.50
	Other non-current liabilities	133.82	148.21
	Total non-current liabilities	3,010.53	4,551.54
	Current liabilities		
	Financial liabilities		
	Borrowings	3,048.52	2,416.36
	Trade payables	6,485.15	5,996.05
	Other financial liabilities	1,737.66	2,227.31
	Other current liabilities	156.27	125.98
	Provisions (employee benefit obligations)	403.85	274.51
	Deferred government grants	29.06	29.06
	Total current liabilities	11,860.51	11,069.27
	Total liabilities	14,871.04	15,620.81
	TOTAL EQUITY AND LIABILITIES	81,570.92	75,149.29